,
An Albuquerque marijuana company has announced that it will soon be carrying products from country music star Toby Keith’s cannabis line in its dispensaries.
This isn’t the first time that Albuquerque-based Seven Clover has dabbled in the celebrity weed market. Earlier this year, the company announced it would be selling cannabis from actor Jim Belushi’s production company.
Toby Keith’s Big Dog Cannabis Co. is based in Oklahoma, but the company is now expanding into New Mexico for the first time. The company’s products will be manufactured and packaged in the Land of Enchantment by Seven Clover. The first batch has reportedly been completed already and will be on sale at dispensaries within the next few weeks.
Poll: D.C. Staffers Say Congress Won’t Pass Weed Bills
According to a new poll, Capitol Hill staffers don’t expect any marijuana reform laws to pass this Congress.
“Our survey respondents have been spot-on all year round,” Punchbowl News posted on X. Its latest poll asked staffers and lobbyists to make predictions for the second half of the 118th Congress, “including on impeachment, Ukraine and border security funding, bank CEO clawback pay, cannabis banking, AI and more.”
The Canvass Capitol Hill Survey asked respondents if they expected any cannabis reform bills to pass before the Congress ends, including the SAFER Banking Act, and 71 percent said it was “unlikely.”
The SAFER Banking Act would allow banks and financial institutions to legally work with marijuana companies. The bill has bipartisan support and was expected to do well in the Senate, but it has apparently fallen to the wayside in light of more pressing national matters.
Democratic staffers were more optimistic—29 percent thought cannabis reform was likely, 12 percent said they were unsure and 59 percent said it was unlikely—than Republican staffers—nine percent said it was likely, eight percent said they were unsure and 83 percent said it was unlikely.
Psilocybin Rescheduling Petition Denied Rehearing
A federal court has rejected a doctor’s attempt to force the Drug Enforcement Administration (DEA) to send a psilocybin rescheduling petition to the Food and Drug Administration (FDA).
Washington-based end-of-life doctor Sunil Aggarwal has been battling the DEA for months regarding his petition to reschedule psilocybin mushrooms so that they can be used to treat patients who are near death.
In October, a federal court ruled that the DEA failed to fully explain why it had rejected Aggarwal’s petition and ordered that it reconsider the request. But the judges did not order the agency to forward the petition on to the FDA, a request that had been made by Aggarwal’s legal team.
Last week the U.S. Court of Appeals for the Ninth Circuit rejected Aggarwal’s request for a rehearing to potentially make the DEA pass along the petition. The court did not explain its reason.